← Back to Search

Anti-viral

Ganciclovir implant and oral ganciclovir for Cytomegalovirus Retinitis (GCCRT Trial)

Phase 3
Waitlist Available
Research Sponsored by Johns Hopkins Bloomberg School of Public Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss. To compare a treatment regimen that incorporates highly active local therapy (ganciclovir device) with a treatment regimen that does not.

Eligible Conditions
  • Cytomegalovirus Retinitis
  • Human Immunodeficiency Virus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: Ganciclovir implant and oral ganciclovirExperimental Treatment1 Intervention
Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
Group II: Cidofovir IV (Intravenous)Experimental Treatment1 Intervention
cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ganciclovir implant and oral ganciclovir
1997
Completed Phase 3
~70
Cidofovir
FDA approved

Find a Location

Who is running the clinical trial?

Johns Hopkins Bloomberg School of Public HealthLead Sponsor
423 Previous Clinical Trials
2,123,455 Total Patients Enrolled
5 Trials studying Cytomegalovirus Retinitis
3,178 Patients Enrolled for Cytomegalovirus Retinitis
Douglas Jabs, MDStudy ChairSOCA Chairman's Office
1 Previous Clinical Trials
64 Total Patients Enrolled
1 Trials studying Cytomegalovirus Retinitis
64 Patients Enrolled for Cytomegalovirus Retinitis
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top